Mink Therapeutics Inc (INKT) Stock Price, Quote & News

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilim...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 994 8250

Website: minktherapeutics.com

Address:

149 Fifth Avenue, Suite 500, New York, United States

enkemm Aug. 19 at 4:14 PM

$INKT I truly cannot think of single redeeming quality relative to shorts...they are the barnacles stuck to and sucking nourishment off of the rumps of investors. Indeed....loathsome parasitic creatures whose purpose runs afoul of meaningful capitalistic endeavors. In the immortal words of Lady Macbeth..."out, out damn spot..."

0 · Reply

roguesama Aug. 18 at 11:55 AM

$INKT

0 · Reply

2_logs_higher Aug. 18 at 3:26 AM

$AGEN + $INKT new cd 40 drug, Garo, you better keep your foot on the gas pedal https://www.medicalnewstoday.com/articles/experimental-drug-eliminates-aggressive-breast-skin-cancer-in-small-trial

1 · Reply

d_risk Aug. 16 at 11:21 PM

$INKT - MiNK Therapeutics, Inc. - 10Q - Updated Risk Factors INKT flags new risks: Agenus’ large stake could influence shareholder decisions, potential loss of controlled company status may disrupt operations, and Agenus selling its shares could trigger a change of control. #Biotechnology #EquityStake #OperationalRisk #ChangeOfControl #ShareholderInfluence 🟢 Added 🟠 Removed https://d-risk.ai/INKT/10-Q/2025-08-14

1 · Reply

Dancady1 Aug. 16 at 12:56 PM

$INKT hopefully old resistance acts as support

0 · Reply

Dgun Aug. 15 at 3:58 PM

$INKT gap filled

1 · Reply

enkemm Aug. 15 at 2:18 PM

$INKT The day traders and shorts are waltzing together right now...but the dance will end soon enough

0 · Reply

Slimwolf Aug. 15 at 1:44 PM

$INKT shorts are in big trouble as this moves up on thin volume. They can’t get out without paying up. Let’s see $20

0 · Reply

roguesama Aug. 15 at 1:43 PM

$INKT SSR Today

0 · Reply

Dead_Pony Aug. 15 at 12:39 PM

$INKT wow

0 · Reply

MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:30 AM EDT - 5 days ago

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Jul 31, 2025, 8:30 AM EDT - 19 days ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

Jul 15, 2025, 8:21 AM EDT - 5 weeks ago

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Jul 11, 2025, 12:33 PM EDT - 5 weeks ago

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

Jun 10, 2025, 1:33 PM EDT - 2 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 2, 2025, 9:29 AM EDT - 2 months ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

May 15, 2025, 1:21 PM EDT - 3 months ago

MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:30 AM EDT - 3 months ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

Mar 18, 2025, 11:28 AM EDT - 5 months ago

MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 7:30 AM EDT - 5 months ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mar 4, 2025, 7:30 AM EST - 6 months ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:30 AM EST - 6 months ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 6 months ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Jan 23, 2025, 2:13 PM EST - 7 months ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Dec 18, 2024, 9:45 AM EST - 8 months ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Nov 14, 2024, 10:47 AM EST - 9 months ago

MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript

Nov 11, 2024, 7:30 AM EST - 10 months ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 7, 2024, 10:00 AM EST - 10 months ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Oct 31, 2024, 9:15 AM EDT - 10 months ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 8, 2024, 7:30 AM EDT - 11 months ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 4, 2024, 9:10 AM EDT - 11 months ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Aug 13, 2024, 2:51 PM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Jul 31, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

May 22, 2024, 7:30 AM EDT - 1 year ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 14, 2024, 11:07 AM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:30 AM EDT - 1 year ago

MiNK Reports First Quarter 2024 Results

May 13, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

Apr 30, 2024, 7:30 AM EDT - 1 year ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 8, 2024, 12:00 PM EDT - 1 year ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Mar 21, 2024, 2:20 PM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 7, 2024, 7:30 AM EST - 1 year ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 6, 2024, 8:30 AM EST - 1 year ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

$MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene$

Jan 30, 2024, 8:00 AM EST - 1 year ago

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Dec 20, 2023, 7:30 AM EST - 1 year ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Nov 9, 2023, 7:00 AM EST - 1 year ago

MiNK Therapeutics Reports Third Quarter 2023 Results

Nov 3, 2023, 12:00 PM EDT - 1 year ago

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Oct 30, 2023, 8:00 AM EDT - 1 year ago

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Sep 27, 2023, 9:05 AM EDT - 2 years ago

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Aug 24, 2023, 8:30 AM EDT - 2 years ago

MiNK Therapeutics to Participate in September Investor Conferences

Aug 10, 2023, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Reports Second Quarter 2023 Results

Jul 28, 2023, 8:30 AM EDT - 2 years ago

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

May 22, 2023, 8:30 AM EDT - 2 years ago

MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference

May 18, 2023, 8:30 AM EDT - 2 years ago

MiNK's Novel FAP-CAR-iNKT Presented at ASGCT

May 14, 2023, 2:25 PM EDT - 2 years ago

MiNK Therapeutics, Inc. (INKT) Q1 2023 Earnings Call Transcript

May 11, 2023, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results

enkemm Aug. 19 at 4:14 PM

0 · Reply

roguesama Aug. 18 at 11:55 AM

$INKT

0 · Reply

2_logs_higher Aug. 18 at 3:26 AM

$AGEN + $INKT new cd 40 drug, Garo, you better keep your foot on the gas pedal https://www.medicalnewstoday.com/articles/experimental-drug-eliminates-aggressive-breast-skin-cancer-in-small-trial

1 · Reply

d_risk Aug. 16 at 11:21 PM

1 · Reply

Dancady1 Aug. 16 at 12:56 PM

$INKT hopefully old resistance acts as support

0 · Reply

Dgun Aug. 15 at 3:58 PM

$INKT gap filled

1 · Reply

enkemm Aug. 15 at 2:18 PM

$INKT The day traders and shorts are waltzing together right now...but the dance will end soon enough

0 · Reply

Slimwolf Aug. 15 at 1:44 PM

$INKT shorts are in big trouble as this moves up on thin volume. They can’t get out without paying up. Let’s see $20

0 · Reply

roguesama Aug. 15 at 1:43 PM

$INKT SSR Today

0 · Reply

Dead_Pony Aug. 15 at 12:39 PM

$INKT wow

0 · Reply

MalekJ Aug. 15 at 12:16 PM

$LIMN $INKT looks thin this morning. trade your plan.

0 · Reply

topstockalerts Aug. 15 at 12:04 PM

$INKT can she push higher?

0 · Reply

JarvisFlow Aug. 15 at 11:30 AM

HC Wainwright & Co. updates rating for MiNK Therapeutics ( $INKT ) to Buy, target set at 35.

0 · Reply

GerardGielen97 Aug. 15 at 11:10 AM

$INKT 20 today?

0 · Reply

MalekJ Aug. 14 at 6:40 PM

$LIMN $INKT Both look ready for a big move, trade your plan.

0 · Reply

Biotechguy21 Aug. 14 at 4:00 PM

$INKT going much lower!

0 · Reply

Ron_Burn Aug. 14 at 3:02 PM

$INKT needs to go above $20

0 · Reply

Fonzinatrix Aug. 14 at 2:03 PM

$INKT bargain prices🎉👍

0 · Reply

sameh1982 Aug. 14 at 1:59 PM

$INKT With this positive report and news , we should have earning today 🙏🏻

0 · Reply

sameh1982 Aug. 14 at 1:58 PM

$INKT Up 👆🏻👆🏻👆🏻👆🏻👆🏻

0 · Reply

Peaceouty Aug. 14 at 1:49 PM

$INKT Odd to not file the 10-q at the same time.

1 · Reply

Biotechguy21 Aug. 14 at 1:36 PM

$INKT what a pos. 🤡🤡😂😂

0 · Reply

Market Cap	59.43M
Revenue (ttm)	0.00
Net Income (ttm)	-9.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	77,146
Avg Vol	1,244,716
Day's Range	N/A - N/A
Shares Out	3.99M
Stochastic %K	46%
Beta	0.33
Analysts	Sell
Price Target	$39.00